Wall Street Zen Downgrades Bio-Rad Laboratories (NYSE:BIO) to Hold

Bio-Rad Laboratories (NYSE:BIO) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

BIO has been the subject of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Wells Fargo & Company upped their price target on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, Citigroup raised their price objective on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bio-Rad Laboratories presently has an average rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Stock Down 12.2%

BIO opened at $256.87 on Friday. The firm’s 50 day simple moving average is $305.47 and its two-hundred day simple moving average is $301.52. The company has a market capitalization of $6.93 billion, a PE ratio of 9.20 and a beta of 1.18. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $343.12. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.06). Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The company had revenue of $693.20 million during the quarter, compared to analysts’ expectations of $694.64 million. During the same quarter last year, the company earned $2.90 earnings per share. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. As a group, equities analysts forecast that Bio-Rad Laboratories will post 10.81 EPS for the current year.

Hedge Funds Weigh In On Bio-Rad Laboratories

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quent Capital LLC bought a new stake in Bio-Rad Laboratories in the 3rd quarter valued at $25,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Bio-Rad Laboratories by 3,633.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock worth $27,000 after purchasing an additional 109 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Bio-Rad Laboratories by 52.9% in the third quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after buying an additional 36 shares in the last quarter. Danske Bank A S purchased a new stake in shares of Bio-Rad Laboratories in the fourth quarter worth about $30,000. Finally, Geneos Wealth Management Inc. boosted its stake in Bio-Rad Laboratories by 115.2% during the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

More Bio-Rad Laboratories News

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Management outlined a 2026 program to expand margins via operational improvements and cost actions, which could improve profitability over time. Bio‑Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance
• Positive Sentiment: Management reiterated a focus on operational fixes and provided a slide deck and detailed Q&A on the call — useful for modeling forward margin improvement timing and one‑time items. Q4 results presentation
• Neutral Sentiment: FY‑2026 revenue guidance is modest: management expects roughly flat to low‑single‑digit top‑line growth (about 0.5%–1.5%) with a revenue target around ~$2.6B — implies conservative near‑term growth expectations. Bio‑Rad Reports Fourth‑Quarter and Full‑Year 2025 Financial Results
• Neutral Sentiment: The company provided a full earnings call transcript and presentation that disclose drivers of the quarter and planned cost actions; these documents are important for forecasting the timing and magnitude of margin recovery. Earnings call transcript
• Negative Sentiment: Q4 EPS missed consensus: $2.51 actual vs. $2.57 expected, and revenue of $693.2M narrowly missed estimates — EPS declined from $2.90 a year ago, signaling pressure on short‑term earnings momentum. Q4 earnings miss
• Negative Sentiment: The company reported a negative net margin (reported -26.4%), which likely reflects discrete charges or restructuring that compressed reported profitability and increased investor uncertainty. Market summary and ratios
• Negative Sentiment: Market reaction was sharp: shares dropped with elevated volume after the print and guidance; the combination of an earnings miss and conservative/ muted revenue growth guidance likely triggered the sell‑off. Shares tumble after Q4 miss

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.